The Access Challenge in European Neuro-Degeneration

The approvals of lecanemab and donanemab by the European Commission represent a historic clinical milestone, introducing the first disease-modifying therapies for early symptomatic Alzheimer’s disease. However, securing regulatory marketing authorisation is only the first step. The true battlefield for amyloid-targeting therapies lies in the European market access and reimbursement landscape.

Unlike the United States, where commercial adoption is driven by private payer coverage and physician adoption, European commercialisation is governed by national Health Technology Assessment (HTA) bodies. These organisations—including NICE in the UK, the G-BA in Germany, and HAS in France—evaluate not just clinical efficacy, but absolute cost-effectiveness and systemic healthcare resource utilisation. Navigating these regional reimbursement pathways requires specialised commercial leadership with deep HTA and market access expertise.

Navigating the European HTA Deficit

The commercialization of disease-modifying dementia treatments has encountered significant friction from European HTA bodies, primarily due to the high cost of the therapies and the substantial infrastructure burden they impose on public healthcare systems:

• The UK (NICE) Bottleneck: In the UK, NICE has issued draft guidance declining to recommend both lecanemab and donanemab for NHS use, citing that the clinical benefits (modest slowing of cognitive decline) do not justify the high drug costs and the intensive safety monitoring required. The manufacturers are actively navigating appeals and consultations to establish patient-access schemes.

• Germany's (G-BA) Benefit Assessment: In Germany, the Federal Joint Committee (G-BA) concluded that lecanemab offered "no evidence of added benefit" compared to the existing standard of care. This classification severely weakens the manufacturer's negotiating leverage during subsequent price negotiations with the National Association of Statutory Health Insurance Funds.

• Infrastructure Constraints: Both therapies require regular intravenous infusions and intensive MRI safety monitoring to check for Amyloid-Related Imaging Abnormalities (ARIA—brain swelling or microhaemorrhages). Most public health systems lack the diagnostic and clinical capacity to manage this volume of monitoring, creating a significant barrier to commercial adoption.

Innovative Pricing and Risk-Sharing Models

To bypass these reimbursement bottlenecks, commercial leaders in speciality pharma must move beyond traditional volume-based pricing models. Sponsoring companies are forced to design and propose innovative risk-sharing and value-based agreements:

• Outcome-Based Rebates: Guaranteeing price refunds or discounts to national health services if patients fail to meet predefined cognitive stability targets.

• Infrastructure Co-Investment: Partnering with private diagnostic providers or investing in local infusion clinics to relieve the capacity burden on public hospitals, thereby de-risking the operational cost for health systems.

• Sub-Population Targeting: Restricting reimbursement requests to specific high-responder patient subsets—such as ApoE ε4 non-carriers or heterozygotes—to optimise the cost-benefit ratio for HTA assessors.

Sourcing Strategic Market Access Leadership

As speciality pharma companies scale their neuro-degeneration pipelines in Europe, the demand for Chief Commercial Officers (CCOs) and VP of Global Market Access with deep regional HTA experience has reached a critical level.

RSA prioritises several core competencies when sourcing commercial leadership in this space:

• European HTA Negotiation Track Record: A proven history of successfully negotiating complex reimbursement packages with NICE, G-BA, and HAS, navigating both the technical health economics and the political dynamics of public payers.

• Health Economics and Outcomes Research (HEOR) Mastery: The capability to lead HEOR teams in building real-world evidence (RWE) models that demonstrate long-term cost savings (e.g., delaying institutional care) to offset high acquisition costs.

• Innovative Contracting Design: Experience in structuring risk-sharing, annuity pricing, and value-based contracting models that satisfy national cost-containment mandates.

The commercial viability of next-generation Alzheimer's therapies will not be decided by clinical trial readouts, but by the strategic capability of market access teams. Having the right commercial leadership is the difference between a validated breakthrough and a dormant, non-reimbursed therapeutic asset.